News
The delays, first revealed in Regeneron’s Q2 report, were chalked up to manufacturing issues at Novo Nordisk-owned plants.
Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...
Pharmaceutical Technology on MSN1d
Novo’s facility issues delay FDA decisions on Regeneron’s Eylea HD
Before Novo arrived as its owner, issues at the Bloomington facility caused a two-month delay for Eylea HD’s FDA approval ...
TipRanks on MSN2d
Regeneron says FDA delayed review of two Eylea HD submissions
Pharmaceuticals announced that the Food and Drug Administration has extended the target action dates to Q4 of 2025 for two Eylea ...
Regeneron Pharmaceuticals ( NASDAQ: REGN) announced that the U.S. FDA has extended the target action dates for two regulatory ...
* Q4 earnings per share view $3.03, revenue view $1.30 billion -- Thomson Reuters I/B/E/S * Regeneron Pharmaceuticals Inc - sees single digit percentage growth over 2016 for eylea U.S. net product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback